BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-225@pharmaconomics
DTSTAMP:20260707T015436Z
DTSTART;VALUE=DATE:20261114
DTEND;VALUE=DATE:20261115
SUMMARY:CYTK PDUFA — aficamten
DESCRIPTION:The FDA's approval decision on aficamten for obstructive hypertrophic cardiomyopathy is due Nov 14\, 2026. A green light opens the market\; a complete response letter (CRL) usually sinks the stock.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1061983/000119312526206360/cytk-ex99_1.htm\n\nTrack it: https://pharmaconomics.com/e/225
URL:https://pharmaconomics.com/e/225
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:CYTK catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR